With shares of JPMorgan Chase & Co. (NYSE:JPM) trading around $55, is JPM an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
JPMorgan Chase is a financial holding company that provides various financial services worldwide. The company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management, and private equity. Financial services companies like JPMorgan Chase are essential for well-functioning economies around the world.
JPMorgan is suing the Federal Deposit Insurance Corp. to recover more than $1 billion tied to its purchase of Washington Mutual when that bank failed in 2008. In a federal court complaint, the biggest U.S. bank said that the FDIC failed to honor obligations under the Washington Mutual agreement, and that has subjected JP Morgan to massive liability. The FDIC became the receiver for Seattle-based Washington Mutual when it collapsed during the height of the financial crisis in September 2008. It was the largest bank failure in U.S. history. The FDIC brokered the sale of Washington Mutual’s assets to JP Morgan for $1.9 billion. JPMorgan said the FDIC made promises to indemnify or protect the bank against liabilities if it stepped in.
Top Mid Cap Stocks To Watch For 2014: Fairway Group Holdings Corp (FWM)
Fairway Group Holdings Corp., incorporated on September 29, 2006, operates in the retail food industry, selling fresh, natural and organic products, prepared foods, and specialty and gourmet offerings along with a assortment of conventional groceries. The Company focuses on perishable product categories, which include produce, natural and organic, deli, specialty, cheese, butcher, seafood, bakery, coffee and kosher foods. Its non-perishable product categories consist of conventional groceries, as well as specialty foods. It operates two stores on the West Side of Manhattan, New York. As of September 24, 2012, it operated 11 locations in the Greater New York City metropolitan area, three of which include Fairway Wines & Spirits stores.
The Company’s natural and organic product categories include fruits and vegetables, natural and fresh juices, organic OBE beef and organic chicken, fresh organic peanut butter and natural almond butter, fresh roasted coffees an d loose teas, dried fruits and nuts, full assortment of natural and organic groceries, cold cuts and cheeses, breads, supplements (homeopathy, vitamins, herbs), nutritional bars and protein powders, health and beauty aids, dairy, including Fairway-branded organic milk, eggs, including Fairway-branded organic eggs, vegetarian dairy alternatives, frozen foods, e gluten-free selections, baby food and baby care items and cleaning products. It offers a classic New York deli counter. It carries smoked salmon prepared using its own recipe and hand-craft its own fresh mozzarella daily.
The Company’s Specialty Imports and Specialty Grocery departments provide shoppers with specialty and gourmet items, such as Lapalisse pure and virgin nut oils; authentic Sicilian foodstuffs; Burgundy’s organic La Trinquelinette fruit preserves made in small batches using only unrefined raw cane sugar; ready-to-eat vacuum-packed beets from the Loire Valley; L’Herbier de Milly La Foret v erbena, hibiscus, peppermint and linden blossom infusions; L! a Quiberonnaise Vintage Sardines from Brittany, France; Pruneaux d’Agen (stuffed prunes), and Royal Medjool dates, Quercy’s soft dried figs and apricots. It carries approximately 115 varieties of specialty olive oil, including numerous imported unfiltered olive oils, and offer all-day, every day tasting of olive oils in each of its stores.
The Company has meat delivered every day and it is cut and packaged at each of its stores within 24 hours of receipt. It also receives daily deliveries of fresh ice-packed chicken. It offers 50 to 80 different selections of fresh fish and seafood in each store every day. It utilizes a combination of on-site and centralized bakeries to produce our baked goods. Its full-service bakery prepares its signature cookies, tarts, cupcakes, baguettes and bagels. It offers over 100 types of artisanal coffee beans sold by the pound, as well as over a dozen varieties of Fair Trade certified and organic coffee.
The Company offe rs an array of kosher options, including Fairway’s branded products, its conventional and specialty groceries, its coffee, as well as its baked goods, dairy, organic, gluten-free, imported and frozen items. It offers a variety of cuts of kosher poultry, red meat and seafood. It carries a range of conventional grocery items. Its grocery aisles are stacked high with the national brand names Tide, Bounty, Kleenex, Charmin, Lysol, Poland Spring, Oreo, Cheerios, Lipton, Hershey’s, Coke, Green Giant, and many more. In addition, it offers an array of ethnic groceries that cater to each store’s local demographic.
- [By Matt Jarzemsky]
The group’s worst performer this year is New York City-area grocer Fairway Group Holdings Corp.(FWM), off 58% in 2013. Fairway is also among the farthest from its 52-week high, closing Thursday at $7.57 after trading as high as $28.87 in July.
- [By Leslie Patton]
Whole Foods is facing increased competition from expanding organic and natural-food sellers including Fairway Group Holdings Corp. (FWM) and Sprouts Farmers Market Inc. (SFM) The chain has been adding more of its 365 private-label brand items to attract price-conscious shoppers. Sales at stores open at least a year rose 5.9 percent in the fourth quarter, which ended Sept. 29, the slowest growth in 15 quarters.
- [By Jason Moser]
You can be forgiven if you’ve never heard of Fairway Group Holdings (NASDAQ: FWM ) . The company is responsible for Fairway Market, a small chain of high-end grocery stores currently in and around the greater New York City metropolitan area.
- [By Rich Duprey]
Indeed, shoppers can even find natural and organic produce at Wal-Mart, and with Fairway Group Holdings (NASDAQ: FWM ) having gone public earlier this year, there’s no shortage of places shoppers can choose from to buy their all-natural produce. What is Sprouts offering that differentiates it from all of its rivals? Simply counting on a growth-by-expansion policy entails a lot of risk, so the only thing I see is its claim of better product selection and value.
Top Mid Cap Stocks To Watch For 2014: GASFRAC Energy Services Inc (GFS)
GASFRAC Energy Services Inc. (GASFRAC) is an oil and gas service company, whose business is to provide liquid petroleum gas (LPG) fracturing services to oil and gas companies in Canada and the United States of America. As of December 31, 2011, GASFRAC had three 32 tons and nine 100 tons sand storage vessels, 47 fracturing pumpers, 150 LPG storage tanks and related equipment. GASFRAC’s services are marketed and operated under the name of its wholly owned subsidiary GASFRAC Energy Services Limited Partnership. The Company has commercialized the use of LPG as the fracturing fluid. The Company’s subsidiaries include GASFRAC Services GP Inc., GASFRAC US Holdings Inc., GASFRAC Inc., GASFRAC Energy Services (US) Inc. and GASFRAC Luxembourg S.a.r.l. Advisors’ Opinion:
- [By Sarah Jones]
G4S Plc (GFS) sank 15 percent to 260 pence. The security company reported a lower operating margin for the first quarter, citing challenging economic and trading conditions in continental Europe. It expects the margin trend to continue for the full year.
- [By Sofia Horta e Costa]
G4S Plc (GFS) dropped 1.7 percent to 225.6 pence. Goldman Sachs Group Inc. reiterated its “conviction sell” recommendation on the provider of security services, citing continued pressure on its profit margin in the second quarter.
Top Mid Cap Stocks To Watch For 2014: Insulet Corporation(PODD)
Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod disposable insulin infusion device and the handheld wireless personal diabetes manager to provide diabetes management solution for people with insulin-dependent diabetes. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors; and delivers durable medical equipment to endocrinologists, insurers, and clients. Insulet Corporation was founded in 2000 and is headquartered in Bedford, Massachusetts.
- [By Rich Smith]
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of downgrades for document storage company Iron Mountain (NYSE: IRM ) and insulin treatments-equipment maker Insulet (NASDAQ: PODD ) . But the headlines aren’t all bad, so before we break the bad news to you, let’s start off on a bright note about…
- [By James Brumley]
And just for the record, theme-based buyout speculation doesn’t improve your chances of picking an acquisition target. Back in 2012 after Bristol-Myers Squibb (BMY) bought Amylin for control of its diabetes pipeline following the purchase of Neighborhood Diabetes by Insulet (PODD), pundits were sure it would spark a wave of other diabetes-driven acquisitions. Those other M&A candidates began getting bid up, but as it turns out, no more meaningful buyouts materialized in the diabetes space.
Top Mid Cap Stocks To Watch For 2014: Quest Diagnostics Inc (DGX)
Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.
The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.
The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing thr ough its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.
The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical directo r services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.
The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.
In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.
Healthcare Information Technology
The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic d ocument management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics’ Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient’s account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.
Clinical Trials Testing
The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People’s Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.
Life Insurer Services
The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant’s home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examina tions. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.
The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation’s workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.
Diagnostic Produc ts include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are s old under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.
HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.
The Company competes with Laboratory Corporation of America Holdings, Inc.
- [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]
Quest Diagnostics Inc.(DGX) agreed to buy Summit Health to expand its prevention and wellness business, following a string of recent acquisitions. Michigan-based Summit Health provides on-site prevention and wellness programs for employers, health plans, retail clinics and other organizations.
- [By Monica Gerson]
Quest Diagnostics (NYSE: DGX) today announced that it has entered into a definitive purchase agreement under which Quest will acquire Summit Health. Terms of the transaction were not disclosed. To read the full news, click here. Bayer HealthCare Pharmaceuticals (OTC: BAYRY) and Onyx Pharmaceuticals, an Amgen subsidiary (NASDAQ: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. To read the full news, click here. Barrick Gold (NYSE: ABX) today announced that, further to its release of March 10, 2014, it has completed the divestment of 41.0 million ordinary shares in African Barrick Gold plc, representing in aggregate approximately 10.0 percent of the issued ordinary share capital of ABG, at a price of 275 pence per ordinary share, raising gross proceeds of approximately GBP 113 million (US$188 million). To read the full news, click here. Urban Outfitters (NASDAQ: URBN) dropped in after-hours trading after the company released its fourth quarter results. The firm reported a Q4 EPS of $0.59 versus the Street estimate of $0.55. To read the full news, click here.
Posted-In: Pacific Crest US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
- [By John Udovich]
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50% – a nice return in just two weeks time.
Top Mid Cap Stocks To Watch For 2014: Imprimis Pharmaceuticals Inc (IMMY)
Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company’s Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company’s lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.
Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it ex erts its localized anti-inflammatory and analgesic effect. Transdel is the Company’s transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.
- [By John Udovich]
So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year – making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many…) planned biotech IPOs that have recently been announced publicly:
Top Mid Cap Stocks To Watch For 2014: Seven & i Holdings Co Ltd (SVNDY)
Seven & i Holdings Co., Ltd. is a Japan-based holding company. The Company operates in six business segments. The Convenience Store segment operates convenience stores under the name 7-Eleven through direct operation and franchising. The Super Store segment operates general supermarkets, food supermarkets and specialty stores. The Department Store segment operates department stores with a focus on Seibu. The Food Service segment is engaged in the restaurant business, the contract food business and the fast food business. The Financial-related segment is engaged in the banking service, credit card and electronic money services. The Others segment is engaged in the information technology (IT) business. Advisors’ Opinion:
- [By Jim Jubak]
If you’re a trader, you try to catch these ups and downs. If you’re a longer term trader, you sort of go with Japanese equities. The one that I’ve got in Jubak’s Picks is Toyota Motor, (TM), which trades in New York as an ADR. You can also go with something like Torre Industries (TRYIF), which trades as an ADR in New York as well as on the Tokyo exchange. They’re the world’s largest maker of carbon fiber, good play on exports to the aircraft and car industries. Or you can do something like Seven & I (SVNDY), the Japanese company that owns 7-Elevens around the world. So, those would be my ways to play a weak yen if you want to use Japanese equities for the week and the year ahead.
Top Mid Cap Stocks To Watch For 2014: Advantage Oil & Gas Ltd (AAV)
Advantage Oil & Gas Ltd. and its subsidiaries engage in the acquisition, exploitation, development, and production of oil and gas in the provinces of Alberta and Saskatchewan, Canada. It produces and sells crude oil, natural gas, sulphur, and natural gas liquids primarily through marketing companies. As of February 5, 2013, the companys core properties comprised of Glacier Montney natural gas asset with approximately 80 net sections of land located in Alberta. Advantage Oil & Gas Ltd. was founded in 2001 and is headquartered in Calgary, Canada.
- [By John Udovich]
While Bakken formation oil and gas stocks have grabbed the attention of American investors, small cap Alberta or Saskatchewan oil and gas stocks Advantage Oil & Gas Ltd (NYSE: AAV), Sonde Resources Corp (NYSEMKT: SOQ) and up and coming Centor Energy Inc (OTCBB: CNTO) have been largely overlooked as they seek to exploit oil and gas (including oil sands) in the resource rich Canadian provinces of Alberta or Saskatchewan or seek strategic alternatives for their assets in these areas or themselves. It should be mentioned that Canada’s oil reserves are third only to Venezuela and Saudi Arabia with over 95% of these reserves being the oil sands of Alberta plus that province contains much of the country’s conventional oil reserves as well. In addition, the province of Saskatchewan along with offshore areas of Newfoundland contain substantial production and reserves. Excluding oil sands, Alberta would have 39% of Canada’s remaining conventional oil reserves, followed b y offshore Newfoundland with 28% and Saskatchewan with 27%.
- [By Eric Lam]
Royal Bank gained 1.2 percent as the market value of the nation’s largest lender rose past C$100 billion for the first time. Bankers Petroleum Ltd. and Advantage Oil & Gas Ltd. (AAV) climbed more than 2.7 percent as oil companies advanced. H&R Real Estate Investment Trust and Canadian Apartment Properties REIT added at least 2.5 percent to pace gains among financial stocks. Athabasca Oil Corp. tumbled 9.9 percent after an Alberta court decided to allow an aboriginal group to appeal an approval of the company’s Dover oil-sands project.
Top Mid Cap Stocks To Watch For 2014: HSBC Holdings PLC (HSBC)
HSBC Holdings plc (HSBC), incorporated on January 1, 1959, is a global banking and financial services organizations. As of December 31, 2012, it provided a range of financial services to around 58 million customers through four global businesses: Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Global Private Banking. Its international network covers 81 countries and territories in six geographical regions; Europe, Hong Kong, Rest of Asia-Pacific, Middle East and North Africa, North America and Latin America. As of December 31, 2012, the Company had an international network of some 6,600 offices in 81 countries and territories in six geographical regions; Europe, Hong Kong, Rest of Asia-Pacific, Middle East and North Africa (‘MENA’), North America and Latin America. On May 20, 2012, HSBC Holdings PLC’s wholly owned subsidiary HSBC Bank USA, N.A. and other wholly owned subsidiaries, sold 195 retail branches to First Niagara Bank, N.A. (First Niagara). In May 2012, the Company’s 70.03% owned subsidiary, HSBC Bank Malta plc, sold its card acquiring business to HSBC Merchant Services Ltd. In June 2012, the Company’s indirect wholly owned subsidiary, HSBC Iris Investments (Mauritius) Ltd, sold its 4.73% interest in Axis Bank Limited and 4.74% interest in Yes Bank Limited. In July 2012, its subsidiary, HSBC Europe (Netherlands B.V.), sold its 100% interest in HSBC Credit Zrt, to CentralFund Kockazati Tokealap. On March 31, 2013, Enstar Group Ltd’s subsidiary completed the acquisition from Household Insurance Group Holding Company of HSBC Insurance Company of Delaware and Household Life Insurance Company of Delaware, as well as its three subsidiary insurers.
The Company’s principal banking operations in Europe are HSBC Bank plc in the UK, HSBC France, HSBC Bank A.S. in Turkey, HSBC Bank Malta p.l.c., HSBC Private Bank (Suisse) SA and HSBC Trinkaus & Burkhardt AG. Through these subsid iaries it provides a range of banking, treasury and financia! l services to personal, commercial and corporate customers across Europe. HSBC’s banking subsidiaries in Hong Kong are The Hongkong and Shanghai Banking Corporation Limited and Hang Seng Bank Limited.
The Company offers a range of banking and financial services in the People’s Republic of China, mainly through its local subsidiary, HSBC Bank (China) Company Limited. It also participates indirectly in mainland China through its primary associate, Bank of Communications. Outside mainland China, it conducts business in 21 countries and territories in the Rest of Asia-Pacific region, primarily through branches and subsidiaries of The Hongkong and Shanghai Banking Corporation.
In the Middle East, the Company has network of branches of HSBC Bank Middle East Limited, together with HSBC’s subsidiaries and associates. Its North American businesses are located in the United States, Canada and Bermuda. Operations in the United States are conducted throug h HSBC Bank USA, N.A., and HSBC Finance, a national consumer finance company based near Chicago. HSBC Markets (USA) Inc. is the intermediate holding company of, inter alia, HSBC Securities (USA) Inc. HSBC Bank Canada and HSBC Bank Bermuda operate in their respective countries.
The Company’s operations in Latin America consists of HSBC Bank Brasil S.A.-Banco Multiplo, HSBC Mexico, S.A., HSBC Bank Argentina S.A. and HSBC Bank (Panama) S.A. In addition to banking services, it operates insurance businesses in Brazil, Mexico, Argentina, Panama and a range of smaller markets.
Retail Banking and Wealth Management
Retail Banking and Wealth Management (RBWM) take deposits and provide transactional banking services to enable customers to manage their day-to-day finances and save for the future. It offers credit facilities to assist customers in their short or longer-term borrowing requirements; and we provide financial advisory, broking, insu rance and investment services to help them to manage and pro! tect thei! r financial futures. It develops products designed to meet the needs of specific customer segments, which may include a range of different services and delivery channels. Its customer offerings include deposits and account services; credit and lending, both secured and unsecured, and financial advisory, broking, life insurance manufacturing and asset management.
The Company offers services through four principal channels: branches, self-service terminals, telephone service centres and digital (Internet and mobile). Customers can transact with the bank through a combination of these channels. Its offers include HSBC Premier, HSBC Advance, Wealth Solutions & Financial Planning and Basic Banking. HSBC Premier provide preferential banking services and global recognition to its mass affluent customers and their immediate families. Customers can access emergency travel assistance, priority telephone banking and an online global view of their Premier accounts around th e world. HSBC Advance provides a range of preferential products and services to simplify the banking needs of customers and to help them manage and plan their money to achieve their financial goals and ambitions. Wealth Solutions & Financial Planningis a financial planning process designed around individual customer needs to help its clients to protect, grow and manage their wealth through investment and wealth insurance products manufactured by Global Asset Management, Global Markets and HSBC Insurance and by selected third-party providers. Basic Banking provides banking products and services using global product platforms and globally set service standards.
The Company segment’s its Commercial Banking Business (CMB) into Corporate, to serve both Corporate and Mid-Market companies, and Business Banking, to serve the small and medium-sized enterprises (SME’s) sector. It provides support to companies as they expand both domesti cally and internationally, and ensures a focus on the busine! ss bankin! g segments. It offers a range of financing, both domestic and cross-border, including overdrafts, receivables finance, term loans and syndicated, leveraged, acquisition and project finance. Asset finance is offered in selected sites. The Company provides the services and finance its clients need throughout the trade cycle including; letters of credit, collections, guarantees; receivables finance; supply chain solutions; commodity and structured finance; and risk distribution. HSBC is supporting the development of renminbi as a trade currency, with renminbi capabilities in more than 50 markets. It is a provider of domestic and cross-border payments, collections, liquidity management and account services offering local, regional and global solutions delivered through e-enabled platforms designed to address the current and future needs of its clients. The Company offers business and financial protection, trade insurance, employee benefits, corporate wealth management and a vari ety of other commercial risk insurance products in selected countries.
Global Banking and Markets
Global Banking and Markets (GB&M) provides tailored financial solutions to government, corporate and institutional clients and private investors globally. Managed as a global business, GB&M operates a long-term relationship management approach to build a understanding of clients’ financial requirements. Sector-focused client service teams consisting of relationship managers and product specialists develop financial solutions to meet individual client needs. GB&M is managed as two principal business lines: Global Markets, and Global Banking.
Global Markets operations consist of treasury and capital markets services. Products include foreign exchange; currency, interest rate, bond, credit, equity and other derivatives; government and non-government fixed income and money market instruments; precious metals and exchange-traded futures; equ ity services; distribution of capital markets instruments, a! nd securi! ties services, including custody and clearing services and funds administration to both domestic and cross-border investors. Global Banking offers financing, advisory and transaction services. Its products include capital raising, advisory services, bilateral and syndicated lending, leveraged and acquisition finance, structured and project finance, lease finance and non-retail deposit taking; international, regional and domestic payments and cash management services; and trade services for corporate clients.
Global Private Banking
Global Private Banking (GPB) provides investment management and trustee solutions to high net worth individuals and their families globally. Private Banking services consists of multicurrency and fiduciary deposits, account services, and credit and specialist lending. GPB also accesses HSBC’s universal banking capabilities to offer products and services such as credit cards, Internet banking, and corporate and investmen t banking solutions. Investment Management comprises advisory and discretionary investment services, as well as brokerage across asset classes. This includes a range of investment vehicles, portfolio management, security services and alternatives. Private Trust Solutions comprise trusts and estate planning, designed to protect wealth and preserve it for future generations through structures tailored to meet the individual needs of each client.
- [By fedezaldua]
Indeed, BBVA sells at a similar valuation level but pays a much lower cash yield – BBVA is expected to pay a 4% cash dividend yield in 2014. BBVA trades at 2014 150% tangible book value and 18 times earnings. While you can always acquire a solid international banking institution such as HSBC (HSBC), which pays a 4% cash yield and sells for a significantly lower valuation than both Santander and BBVA, it’s nearly impossible in today’s market to buy an international banking institution that would pay you a 9% cash dividend yield.
- [By Sara Sjolin]
Banks rose, with shares of Royal Bank of Scotland Group PLC (UK:RBS) (RBS) up 0.8%, Barclays PLC (UK:BARC) (BCS) rising 0.4% and sector heavyweight HSBC Holdings PLC (UK:HSBA) (HSBC) (HK:5) 0.3% higher.
- [By MARKETWATCH]
COPENHAGEN (MarketWatch) — European stock markets rose for a fourth straight day on Monday, as investors remained optimistic about the outlook for the U.S. economy after the IMF late last week said this will grow at a faster pace than previously expected. The Stoxx Europe 600 index (XX:SXXP) gained 0.2% to 321.70, on track for its highest closing level since early December. Banks were among advancers, with shares of Banca Monte dei Paschi di Siena Spa (IT:BMPS) up 3.2%, HSBC Holdings PLC (UK:HSBA) (HSBC) rising 0.5% and Commerzbank AG (DE:CBK) 0.7% higher. Among country-specific indexes, the U.K.’s FTSE 100 index (UK:UKX) added 0.4% to 6,631.05 and France’s CAC 40 index (FR:PX1) was flat around 4,194.43. Germany’s DAX 30 index (DX:DAX) put on 0.3% to 9,429.50.
- [By Daniel Inman]
HSBC Holdings PLC (HK:5) (HSBC) , the single largest constituent on the Hang Seng Index, fell 0.5% after the bank said it agreed to sell its 8% stake in Bank of Shanghai to Spain’s Banco Santander S.A. (ES:SAN) . The bank didn’t say how much it was selling the stake for but it valued the holding at $468 million at Sept. 30.